Geron Corp Files 8-K: Procedural Update
Ticker: GERN · Form: 8-K · Filed: Mar 14, 2024 · CIK: 886744
| Field | Detail |
|---|---|
| Company | Geron Corp (GERN) |
| Form Type | 8-K |
| Filed Date | Mar 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, procedural
Related Tickers: GERN
TL;DR
GERN filed an 8-K, looks like a standard update, no big news yet.
AI Summary
On March 14, 2024, Geron Corporation (GERN) filed an 8-K report detailing an "Other Event." The filing does not disclose specific financial transactions or material business developments, but rather serves as a procedural update.
Why It Matters
This filing indicates a routine update or event for Geron Corporation, without revealing immediate material changes to investors.
Risk Assessment
Risk Level: low — The filing is procedural and does not contain information that inherently increases or decreases risk for investors.
Key Players & Entities
- Geron Corporation (company) — Registrant
- GERN (company) — Ticker Symbol
- March 14, 2024 (date) — Filing Date
FAQ
What specific event is reported in this 8-K filing by Geron Corporation?
The filing is categorized under 'Other Events' and does not specify a particular event, suggesting it may be a routine or procedural update.
When was this 8-K report filed by Geron Corporation?
The 8-K report was filed on March 14, 2024.
What is Geron Corporation's primary business as indicated by its SIC code?
Geron Corporation's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where is Geron Corporation's principal executive office located?
Geron Corporation's principal executive offices are located at 919 East Hillsdale Boulevard, Suite 250, Foster City, California 94404.
Does this filing indicate any immediate financial transactions or material business changes for Geron Corporation?
No, the filing is categorized as 'Other Events' and does not detail specific financial transactions or material business changes.
Filing Stats: 490 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-03-14 16:08:52
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value GERN The Nasdaq Stock Mar
Filing Documents
- gern-20240314.htm (8-K) — 46KB
- gern-ex99_1.htm (EX-99.1) — 26KB
- img50521483_0.jpg (GRAPHIC) — 6KB
- 0000950170-24-031475.txt ( ) — 201KB
- gern-20240314.xsd (EX-101.SCH) — 27KB
- gern-20240314_htm.xml (XML) — 5KB
01
Item 8.01 Other Events. On March 14, 2024, Geron Corporation (the "Company") issued a press release announcing the results of the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee, virtually held on March 14, 2024, in connection with the Company's New Drug Application for imetelstat for the treatment of transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes who have failed to respond, or have lost response to, or are ineligible for erythropoiesis-stimulating agents. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GERON CORPORATION Date: March 14, 2024 By: /s/ Scott A. Samuels Name: Scott A. Samuels Title: Executive Vice President, Chief Legal Officer and Corporate Secretary 3